Medpace Holdings Valuation
Is MEDP * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MEDP * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEDP * (MX$6565) is trading above our estimate of fair value (MX$4853.42)
Significantly Below Fair Value: MEDP * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEDP *?
Other financial metrics that can be useful for relative valuation.
What is MEDP *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$12.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6x |
Enterprise Value/EBITDA | 30.9x |
PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does MEDP *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 32.3x | ||
603259 WuXi AppTec | 13.2x | 11.2% | CN¥121.1b |
BRKR Bruker | 28x | 3.6% | US$11.2b |
CRL Charles River Laboratories International | 25.2x | 13.6% | US$11.2b |
TECH Bio-Techne | 62.7x | 15.0% | US$12.7b |
MEDP * Medpace Holdings | 38.7x | 13.8% | Mex$12.1b |
Price-To-Earnings vs Peers: MEDP * is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (32.3x).
Price to Earnings Ratio vs Industry
How does MEDP *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: MEDP * is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the Global Life Sciences industry average (31.8x).
Price to Earnings Ratio vs Fair Ratio
What is MEDP *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 38.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEDP *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.